Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Get the latest news and real-time alerts from Recursion Pharmaceuticals, Inc. (RXRX) stock at Seeking Alpha.

DNA Ginkgo Bioworks Holdings, Inc.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.